Cell manufacturing company raises $19M Series A to increase capacity, staff numbers
A London-based startup that builds machines that convert stem cells into more specific cell types has closed a $19 million Series A round to boost its production capacity and increase its team of 30 staff members to 50.
Mytos is currently “at the limit” of how fast it can build its machines, CEO Ali Afshar told Endpoints News in an interview. And the Series A is designed to increase the build and distribution of its cell production system — simply named the Mytos Platform — and grow its sales and development workforce.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.